New data from ASCO 2025 & clinical performance of Natera’s ultra-sensitive MRD platform

Natera and its collaborators presented >6 oral presentations and >25 posters at ASCO 2025, highlighting the growing impact of circulating tumor DNA (ctDNA) in oncology drug development and clinical decision-making.

This webinar will review new data supporting the use of ctDNA-based molecular disease monitoring to enable patient stratification and early response assessment across solid tumors.

Featured data highlights:

Clinical performance of the Signatera™ Genome assay: 100% specificity and 94% longitudinal sensitivity in a pan-cancer cohort, with analytical detection down to 1 part-per-million (ppm) (George M., et al). Signatera™ Genome is the first and only WGS-based MRD assay to be covered by Medicare.
ctDNA dynamics in perioperative muscle-invasive bladder cancer (MIBC) from the phase III NIAGARA trial (Powles T., et al)
Response monitoring in metastatic breast cancer across treatments–including ADCs, CDK4/6i–where ctDNA dynamics were the strongest predictor of treatment benefit (Razavi P., et al)
Interim findings from DARE, a prospective interventional study, demonstrating feasibility of randomization upon detection of molecular disease (Pusztai L., et al)

Other data presented spanned additional tumor types, including colorectal, gastroesophageal, melanoma, bladder, ovarian, pancreatic, HCC, sarcoma, and others.

Join medical and scientific experts to explore how Natera’s ctDNA platform—anchored by technological innovation, robust clinical evidence, and enabled by extensive commercial infrastructure—is shaping the future of precision oncology trials and clinical decision-making.

Adham Jurdi

Senior oncology medical director - gi malignancies, natera

Adham Jurdi, MD, is a Board-certified Medical Oncologist who specializes in gastrointestinal malignancies. Prior to joining Natera, Dr Jurdi practiced at Austin Cancer Center, SUNY Upstate Medical University and the Syracuse VAMC. Throughout his clinical career, he was involved in GI oncology and precision medicine research

Angel Rodriguez

Senior oncology medical director - breast oncology, natera

Angel Augusto Rodriguez, MD, is a board-certified medical oncologist who specializes in breast medical oncology and conducted clinical research with circulating tumor DNA. Before joining Natera, Dr. Rodriguez practiced at Austin Cancer Centers and Houston Methodist Cancer Center where he was Director of the Clinical Trials Office and the Triple Negative Breast Cancer Clinic. While at Houston Methodist he was the principal investigator of clinical trials and conducted clinical research with circulating tumor DNA.

Adam ElNaggar, M.D.

Senior Oncology Medical Director - GU and GYN, Natera

Adam ElNaggar, MD, joined the oncology team at Natera in 2021. Prior to this, he was at West Cancer Center and Research Institute where he served as Director of Gynecologic Cancer Research, Associate Fellowship Director, and on the National Comprehensive Cancer Network (NCCN) ovarian cancer panel. Dr. ElNaggar earned his medical degree at Indiana University School of Medicine and completed his residency in obstetrics and gynecology at the University of Tennessee Health Science Center in Memphis, TN. He then completed his fellowship in gynecologic oncology at The Ohio State University Comprehensive Cancer Center.

Michael Krainock

Oncology medical director - thoracic, melanoma, head & neck, natera

Michael Krainock, MD, PhD, is a Medical Director in Thoracic Oncology at Natera. Michael is a physician-scientist by training with experience in biotechnology and life sciences innovation. After completing his medical degree at the University of Nevada, Michael went on to earn a PhD at the University of Southern California, studying the epigenetic regulation of epithelial-to-mesenchymal transformation. Michael completed residency training in general surgery at Loma Linda University Medical Center and fellowship training in cardiothoracic surgery at the University of Pittsburgh Medical Center. Michael has also received an MBA from the Gies College of Business - University of Illinois.

moderator

John Simmons

Global vp biopharma and oncology partnerships, natera

John Simmons, PhD currently leads oncology biopharma partnerships at Natera. Before joining Natera, John completed his postdoctoral fellowship at the National Cancer Institute (NCI) and served as Vice President of Translational Medicine at Personal Genome Diagnostics (PGDx). He received his PhD in Tumor Biology from Georgetown University.